Cancer Epidemiology Biomarkers & Prevention, Vol 7, Issue 2 127-134, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Oltipraz chemoprevention trial in Qidong, People's Republic of China: modulation of serum aflatoxin albumin adduct biomarkers

TW Kensler, X He, M Otieno, PA Egner, LP Jacobson, B Chen, JS Wang, YR Zhu, BC Zhang, JB Wang, Y Wu, QN Zhang, GS Qian, SY Kuang, X Fang, YF Li, LY Yu, HJ Prochaska, NE Davidson, GB Gordon, MB Gorman, A Zarba, C Enger, A Munoz and KJ Helzlsouer
Department of Environmental Health Sciences, Johns Hopkins School of Hygiene and Public Health, Baltimore, Maryland 21205, USA. tkensler@jhsph.edu

In 1995, 234 adults from Qidong, People's Republic of China, were enrolled and followed in a Phase IIa 4-methyl-5-(N-2-pyrazinyl)-1,2-dithiole-3-thione (oltipraz) chemoprevention trial. Residents of this area are at high risk for development of hepatocellular carcinoma, in part due to consumption of aflatoxin-contaminated foods. The intervention was a randomized, placebo-controlled, double-blind study. Elements of the study design and clinical outcomes have been recently published (Jacobson et al, Cancer Epidemiol. Biomark. Prev., 6: 257-265, 1997). The primary objective was to conduct a preliminary assessment of the ability of oltipraz to modulate levels of a validated biomarker of aflatoxin exposure and of the risk of hepatocellular carcinoma by determining levels of aflatoxin-albumin adducts in sera. Healthy eligible individuals were randomized into three arms to receive p.o. 125 mg of oltipraz daily, 500 mg of oltipraz weekly, or placebo for 8 weeks. There were no consistent changes in biomarker levels in the placebo arm over the 16-week observation period, nor was any apparent effect observed in the arm receiving 125 mg of oltipraz each day. However, individuals receiving 500 mg of oltipraz once a week for 8 weeks showed a triphasic response to oltipraz. No effect was observed during the 1st month of the intervention, whereas a significant (P = 0.001) diminution in adduct levels was observed during the 2nd month of active intervention and during the lst month of follow-up. A partial rebound in adduct levels toward baseline values was observed during the 2nd month postintervention. Linear regression models up to week 13 confirmed a significant (P = 0.008) weekly decline of biomarker levels in the group receiving 500 mg of oltipraz once a week. However, despite these effects relative to baseline values within the 500-mg weekly arm, there were no statistically significant differences in biomarker trajectories between treatment arms. The genotype for glutathione S-transferase M1, an oltipraz-inducible isoform involved in the detoxification of aflatoxin B1, did not appear to affect either baseline levels or rates of decline in the biomarker. A follow-up Phase IIb trial with a longer intervention period will be necessary to determine the full extent to which aflatoxin biomarker burden can be reduced and whether diminution of biomarkers can be sustained over the long term.

This article has been cited by other articles:

				L. Tang, M. Tang, L. Xu, H. Luo, T. Huang, J. Yu, L. Zhang, W. Gao, S. B. Cox, and J.-S. Wang Modulation of aflatoxin biomarkers in human blood and urine by green tea polyphenols intervention Carcinogenesis, February 1, 2008; 29(2): 411 - 417. [Abstract] [Full Text] [PDF]

				T. Peng, L.-Q. Li, M.-H. Peng, Z.-M. Liu, T.-W. Liu, Y. Guo, K.-Y. Xiao, Z. Qin, X.-P. Ye, X.-S. Mo, et al. Evaluation of oxidative stress in a group of adolescents exposed to a high level of aflatoxin B1 a multi-center and multi-biomarker study Carcinogenesis, November 1, 2007; 28(11): 2347 - 2354. [Abstract] [Full Text] [PDF]

				C. Cavin, T. Delatour, M. Marin-Kuan, D. Holzhauser, L. Higgins, C. Bezencon, G. Guignard, S. Junod, J. Richoz-Payot, E. Gremaud, et al. Reduction in Antioxidant Defenses may Contribute to Ochratoxin A Toxicity and Carcinogenicity Toxicol. Sci., March 1, 2007; 96(1): 30 - 39. [Abstract] [Full Text] [PDF]

				X. Yu, P. A. Egner, J. Wakabayashi, N. Wakabayashi, M. Yamamoto, and T. W. Kensler Nrf2-mediated Induction of Cytoprotective Enzymes by 15-Deoxy-{Delta}12,14-Prostaglandin J2 Is Attenuated by Alkenal/one Oxidoreductase J. Biol. Chem., September 8, 2006; 281(36): 26245 - 26252. [Abstract] [Full Text] [PDF]

				S. Sharma, P. Gao, and V. E. Steele The chemopreventive efficacy of inhaled oltipraz particulates in the B[a]P-induced A/J mouse lung adenoma model Carcinogenesis, August 1, 2006; 27(8): 1721 - 1727. [Abstract] [Full Text] [PDF]

				Y. Zhang and G. B. Gordon A strategy for cancer prevention: Stimulation of the Nrf2-ARE signaling pathway Mol. Cancer Ther., July 1, 2004; 3(7): 885 - 893. [Abstract] [Full Text] [PDF]

				C. W. Nho and P. J. O'Dwyer NF-{kappa}B Activation by the Chemopreventive Dithiolethione Oltipraz Is Exerted through Stimulation of MEKK3 Signaling J. Biol. Chem., June 18, 2004; 279(25): 26019 - 26027. [Abstract] [Full Text] [PDF]

				B. D. Roebuck, T. J. Curphey, Y. Li, K. J. Baumgartner, S. Bodreddigari, J. Yan, S. J. Gange, T. W. Kensler, and T. R. Sutter Evaluation of the cancer chemopreventive potency of dithiolethione analogs of oltipraz Carcinogenesis, December 1, 2003; 24(12): 1919 - 1928. [Abstract] [Full Text] [PDF]

				C. Wang, T. K. Bammler, and D. L. Eaton Complementary DNA Cloning, Protein Expression, and Characterization of Alpha-Class GSTs from Macaca fascicularis Liver Toxicol. Sci., November 1, 2002; 70(1): 20 - 26. [Abstract] [Full Text] [PDF]

				C.P. Wild and P.C. Turner The toxicology of aflatoxins as a basis for public health decisions Mutagenesis, November 1, 2002; 17(6): 471 - 481. [Abstract] [Full Text] [PDF]

				H. Nakamura, K. Okazaki, A. Nishikawa, F. Furukawa, K.-I. Kasahara, M. Miyauchi, T. Imazawa, K. Uchida, and M. Hirose Enhancing Effects of Oltipraz on the Development of Spontaneous Hepatic Lesions in LEC Rats Toxicol Pathol, February 1, 2002; 30(2): 173 - 177. [Abstract] [PDF]

				S.-Y. Chen, C.-J. Chen, S.-R. Chou, L.-L. Hsieh, L.-Y. Wang, W.-Y. Tsai, H. Ahsan, and R. M. Santella Association of Aflatoxin B1-Albumin Adduct Levels with Hepatitis B Surface Antigen Status among Adolescents in Taiwan Cancer Epidemiol. Biomarkers Prev., November 1, 2001; 10(11): 1223 - 1226. [Abstract] [Full Text] [PDF]

				A. Camoirano, M. Bagnasco, C. Bennicelli, C. Cartiglia, J.-B. Wang, B.-C. Zhang, Y.-R. Zhu, G.-S. Qian, P. A. Egner, L. P. Jacobson, et al. Oltipraz Chemoprevention Trial in Qidong, People's Republic of China: Results of Urine Genotoxicity Assays as Related to Smoking Habits Cancer Epidemiol. Biomarkers Prev., July 1, 2001; 10(7): 775 - 783. [Abstract] [Full Text] [PDF]

				J.-S. Wang, S. Abubaker, X. He, G. Sun, P. T. Strickland, and J. D. Groopman Development of Aflatoxin B1-Lysine Adduct Monoclonal Antibody for Human Exposure Studies Appl. Envir. Microbiol., June 1, 2001; 67(6): 2712 - 2717. [Abstract] [Full Text]

				J.-S. Wang, T. Huang, J. Su, F. Liang, Z. Wei, Y. Liang, H. Luo, S.-Y. Kuang, G.-S. Qian, G. Sun, et al. Hepatocellular Carcinoma and Aflatoxin Exposure in Zhuqing Village, Fusui County, People's Republic of China Cancer Epidemiol. Biomarkers Prev., February 1, 2001; 10(2): 143 - 146. [Abstract] [Full Text]

				T. K. Bammler, D. H. Slone, and D. L. Eaton Effects of Dietary Oltipraz and Ethoxyquin on Aflatoxin B1 Biotransformation in Non-Human Primates Toxicol. Sci., March 1, 2000; 54(1): 30 - 41. [Abstract] [Full Text] [PDF]

				S. S. Wang, J.P. O'Neill, G.-S. Qian, Y.-R. Zhu, J.-B. Wang, H. Armenian, A. Zarba, J.-S. Wang, T. W. Kensler, N. F. Cariello, et al. Elevated HPRT mutation frequencies in aflatoxin-exposed residents of Daxin, Qidong County, People's Republic of China Carcinogenesis, November 1, 1999; 20(11): 2181 - 2184. [Abstract] [Full Text] [PDF]

				Prevention of Cancer in the Next Millennium: Report of the Chemoprevention Working Group to the American Association for Cancer Research Cancer Res., October 1, 1999; 59(19): 4743 - 4758. [Full Text] [PDF]

				J.-S. Wang, X. Shen, X. He, Y.-R. Zhu, B.-C. Zhang, J.-B. Wang, G.-S. Qian, S.-Y. Kuang, A. Zarba, P. A. Egner, et al. Protective Alterations in Phase 1 and 2 Metabolism of Aflatoxin B1 by Oltipraz in Residents of Qidong, People's Republic of China J Natl Cancer Inst, February 17, 1999; 91(4): 347 - 354. [Abstract] [Full Text] [PDF]